JP2007045829A5 - - Google Patents

Download PDF

Info

Publication number
JP2007045829A5
JP2007045829A5 JP2006229517A JP2006229517A JP2007045829A5 JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5 JP 2006229517 A JP2006229517 A JP 2006229517A JP 2006229517 A JP2006229517 A JP 2006229517A JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5
Authority
JP
Japan
Prior art keywords
igfbp
amino acid
binding agent
specific binding
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006229517A
Other languages
English (en)
Japanese (ja)
Other versions
JP4467549B2 (ja
JP2007045829A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007045829A publication Critical patent/JP2007045829A/ja
Publication of JP2007045829A5 publication Critical patent/JP2007045829A5/ja
Application granted granted Critical
Publication of JP4467549B2 publication Critical patent/JP4467549B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006229517A 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体 Expired - Lifetime JP4467549B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005038688A Division JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Publications (3)

Publication Number Publication Date
JP2007045829A JP2007045829A (ja) 2007-02-22
JP2007045829A5 true JP2007045829A5 (https=) 2007-04-05
JP4467549B2 JP4467549B2 (ja) 2010-05-26

Family

ID=22358799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2006229517A Expired - Lifetime JP4467549B2 (ja) 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Country Status (12)

Country Link
US (6) US6506874B1 (https=)
EP (1) EP1141015B1 (https=)
JP (3) JP2002535967A (https=)
AU (1) AU762047B2 (https=)
CA (1) CA2356257C (https=)
CY (1) CY1109452T1 (https=)
DE (1) DE60042550D1 (https=)
DK (1) DK1141015T3 (https=)
ES (1) ES2329220T3 (https=)
IL (3) IL143834A0 (https=)
PT (1) PT1141015E (https=)
WO (1) WO2000040612A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
KR20050071498A (ko) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2274978B1 (en) 2003-09-12 2015-05-20 Tercica, Inc. Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
EP1841443A4 (en) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc METHOD AND SYSTEM FOR TREATING HEART ERRORS
TWI406870B (zh) * 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
FR2892174B1 (fr) 2005-10-14 2007-12-28 Vallourec Mannesmann Oil Gas F Element filete tubulaire muni d'un revetement protecteur sec
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) * 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
US20110045510A1 (en) * 2008-04-03 2011-02-24 Kurt Lang Pegylated insulin-like-growth-factor assay
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
WO2010094906A1 (en) * 2009-07-16 2010-08-26 Arecor Limited The stabilisation of proteins
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
WO2011011072A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
US8906231B2 (en) * 2009-09-10 2014-12-09 Lonza Biologics Plc Method and system for polypeptide purification
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
PL2935320T3 (pl) * 2012-12-18 2020-03-31 Novartis Ag Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3453722A1 (en) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
EP0288451B1 (en) 1987-04-23 1994-08-10 Monsanto Company Secretion of insulin-like growth factor 1 in E. coli
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
ATE148710T1 (de) * 1992-12-02 1997-02-15 Hoechst Ag Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
CA2224859A1 (en) 1996-04-17 1997-10-23 Amitabh Gaur Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
EP0965596A1 (en) 1996-12-27 1999-12-22 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
CA2372393A1 (en) 1999-05-19 2000-11-23 Bassil I. Dahiyat Novel proteins with insulin-like activity useful in the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2007045829A5 (https=)
DK2390265T3 (da) Insulinotropisk peptidderivat med modificeret N-terminal aminosyre
JP2010534684A5 (https=)
SMT201500015B (it) Composizione farmaceutica comprendente (1S)-1,5-anidro-1-[5-(4-etossibenzil)-2- metossi-4-metilfenil]-1-tio-d-glucitolo e un secretagogo dell'insulina
LTPA2017018I1 (lt) Rekombinantinis FSH, įskaitant alfa 2,3- ir alfa 2,6-sialilinimą
PE20090711A1 (es) Region constante de anticuerpo mutante
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
DK1983849T3 (da) Fødevaresammensætning omfattende aminosyrer
DK2035447T3 (da) Polypeptid
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
WO2007060117A3 (de) Chimäre keratinbindende effektorproteine
IL220284A0 (en) Insulin analogues with chlorinated amino acids, compositions comprising the same and uses thereof
PL2004160T3 (pl) Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
FR2900332B1 (fr) Composition dentaire en deux parties.
JP2007510403A5 (https=)
GB0503434D0 (en) Amyloid-binding peptides, analogues and uses thereof
DK1838341T3 (da) Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
ATE546152T1 (de) Bakteriocin-vermittler-peptide
NL1031705A1 (nl) Aminozuurderivaten.
FR2881348B1 (fr) Composition cosmetique nettoyante sous forme solide
GB0704352D0 (en) "Peptide, compositions and uses thereof"
FR2894980B1 (fr) Compositions aqueuses epaissantes et limpides, leur utilisation dans des formulations aqueuses acides, formulations obtenues.
DK1971571T3 (da) Anvendelse af 3-(4-hydroxyphenyl)propionsyreamid i fremstillingen af anti-ældningssammensætninger
ZA201004800B (en) Compound (r)-n*6*-ethyl-6,7-dihydro-5h-indeno(5,6-d)thiazole-2,6-diamine and the use as antipsychotics